source
- Iambic Therapeutics raises $150 million in IPO, begins Nasdaq trading under ticker IAMIambic Therapeutics, an AI-driven drug discovery startup, completed an initial public offering that raised $150 million. The company sold about 9.4 million shares at $16 each and will start tradin…
- Belgian startup Armed Cell Therapeutics acquires Galapagos-derived CAR-T assets for €8 million upfrontArmed Cell Therapeutics, a new Belgian biotech chaired by former Galapagos CEO Paul Stoffels, has taken ownership of several cell therapy programs previously held by Lakefront Biotherapeutics. The…